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TumorigenesisAberrant DNA methylation is a hallmark of cancer but mechanisms contributing to the abnormality remain elu-
sive. We have previously shown that ΔDNMT3B is the predominantly expressed form of DNMT3B. In this study,
we found that most of the lung cancer cell lines tested predominantly expressed DNMT3B isoforms without
exons 21, 22 or both 21 and 22 (a region corresponding to the enzymatic domain of DNMT3B) termed
DNMT3B/ΔDNMT3B-del. In normal bronchial epithelial cells, DNMT3B/ΔDNMT3B and DNMT3B/ΔDNMT3B-del
displayed equal levels of expression. In contrast, in patients with non-small cell lung cancer NSCLC), 111 (93%)
of the 119 tumors predominantly expressed DNMT3B/ΔDNMT3B-del, including 47 (39%) tumors with no detect-
able DNMT3B/ΔDNMT3B. Using a transgenic mouse model, we further demonstrated the biological impact of
ΔDNMT3B4-del, theΔDNMT3B-del isoformmost abundantly expressed in NSCLC, in global DNAmethylation pat-
terns and lung tumorigenesis. Expression of ΔDNMT3B4-del in the mouse lungs resulted in an increased global
DNA hypomethylation, focal DNA hypermethylation, epithelial hyperplastia and tumor formation when chal-
lenged with a tobacco carcinogen. Our results demonstrateΔDNMT3B4-del as a critical factor in developing aber-
rant DNA methylation patterns during lung tumorigenesis and suggest that ΔDNMT3B4-delmay be a target for
lung cancer prevention.
© 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
DNA methylation is a major form of inheritable epigenetic mecha-
nism that regulates the genome. It is important in the dosage compen-
sation of sex chromosome, the repression of retrotransposons, the
maintenance of genome stability, and the coordinated expression of
imprinted genes during development and cellular differentiation
(Edwards et al., 2010; Hansen et al., 2011; Jones, 2002; Robertson,
2001). These epigenetic modiﬁcations direct the establishment of cell
lineage through maintenance of inheritable gene expression proﬁle
and genomic stability (Messerschmidt et al., 2014). Most sites of DNA
methylation occur at cytosine residuals of CpG dinucleotides. In normal
adult tissues, the CpG sites at the repetitive regions of the genome are
heavily methylated, while most of the CpG islands located at or nearDiagnostic Sciences, University
imore, MD 21201, USA.
. This is an open access article underthe promoter regions are unmethylated. DNA methylation is catalyzed
by various DNA methyltransferases. DNMT1 is the enzyme critical for
maintainingDNAmethylation patterns duringDNA replicationwhereas
DNMT3A and DNMT3B canmethylate DNA in de novomanner to devel-
op new methylation patterns in the genome (Bestor, 2000; Li et al.,
1992; Okano et al., 1999). While DNA demethylation may occur in ei-
ther a passive or active manner (Chen et al., 2003; Tahiliani et al.,
2009), mechanisms of these actions remain largely unclear.
In tumorigenesis, the landscape of DNAmethylation patterns chang-
es dramatically, with the general observation of reduced global DNA
methylation and an increase of DNA methylation at certain promoter
CpG islands (Jones, 2012). While extensive efforts have been devoted
to study promoter DNA hypermethylation as a common epigenetic al-
teration in cancers (Jones and Baylin, 2007; Suzuki et al., 2002), global
DNA hypomethylation is recognized as an epigenetic abnormality in
human tumorigenesis as well (Feinberg and Vogelstein, 1987). It is be-
lieved that DNMTs, particularly DNMT3B, are involved in the promoter
hypermethylation in tumorigenesis as DNMT3B is often overexpressed
in cancer tissues (Van Emburgh and Robertson, 2011). However,the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
1341M.Z. Ma et al. / EBioMedicine 2 (2015) 1340–1350mechanisms causing the changes in the DNA methylation landscape
during tumorigenesis due to variant expression of DNMT3B remain
unresolved.
DNMT3B has two subfamilies, DNMT3B and ΔDNMT3B. DNMT3B has
a number of transcription variants resulting from alternative pre-mRNA
splicing, including at least 7 DNMT3Bs and 7 ΔDNMT3Bs (Robertson and
Jones, 1999; L. Wang et al., 2006), but the actual number of DNMT3B var-
iants involved in methylation regulation are likely greater (Ostler et al.,
2007). Interestingly, proteins predicted to be encoded from some of the
variants (DNMT3B3–3B7 and ΔDNMT3B-del) lack the conserved enzy-
matic motifs or possess different peptide sequences due to frame shifts
following the alternative splicing (Robertson and Jones, 1999; J. Wang
et al., 2006; L. Wang et al., 2006). Certain functional consequences of
DNMT3Bs without the enzymatic domain have been reported in an iso-
form or cell context speciﬁc manner. For example, overexpression of
DNMT3b4 is a frequent event in early hepatocarcinogenesis and has
been linked to an increased satellite DNA hypomethylation (Saito et al.,
2002). Forced expression of DNMT3B7 resulted in an attenuated global
DNAmethylation pattern and an increased incidence of mediastinal lym-
phomas in a Myc overexpressing transgenic mouse model (Shah et al.,
2010). Paradoxically, when DNMT3B7was overexpressed in a neuroblas-
tomamodel, it increased global DNAmethylation and induced cell differ-
entiation resulting in a tumor growth inhibition (Ostler et al., 2012). No
signiﬁcant phenotype has, however, been reported when DNMT3B3 and
DNMT3B6 were overexpressed in transgenic mouse models (Linhart
et al., 2007).
In previous studies, we showed that the predominant forms of
DNMT3B transcripts are from ΔDNMT3B in both non-small cell lung can-
cer (NSCLC) cell lines and primary NSCLC tissues (J. Wang et al., 2006; L.
Wang et al., 2006). However, we only analyzed the 5 prime end of the
transcripts in these studies and therefore could not distinguish whether
these transcripts include sequences (exons 21 and 22) required for the
predicted enzymatic domain. Here we report that ΔDNMT3B transcripts
detected in NSCLC are predominantly those lacking of exons 21, 22 or
both 21 and 22 termedΔDNMT3B-del in both NSCLC cell lines and prima-
ry NSCLC tumors. In a transgenic mousemodel with lung speciﬁc expres-
sion ofΔDNMT3B4-del, we demonstrated a role of theDNMT3B isoform in
shaping DNA methylation landscape and early lung tumorigenesis.
2. Materials & Methods
2.1. Cell Lines and Primary Tissues
Human NSCLC lines H157, H226, H292, H358, H460, H522, H596,
H1299, H1792, H1944, Calu-1, SK-MES, and A549, were purchased
from the American Type Cell Culture (Rockville, MD). Cells were cul-
tured in DMEM supplemented with 10% heat-inactivated fetal calf
serum (FCS), 2 mM L-glutamine, 100 IU/ml penicillin, and 100 mg/ml
streptomycin at 37 °C in the presence of 5% CO2. The normal human
bronchial epithelial cell lines HBE1, HBE2, HBE3, HBE4 andHBE5 (kindly
provided by Dr. John Minna of The University of Texas Southwestern
Medical Center, Dallas, TX) were maintained in Keratinocyte-SFM
basal medium (GIBCO) supplemented fresh at the time of use with
0.1–0.2 ng/ml EGF human recombinant and 20–30 μg/ml bovine pitui-
tary extract. The cells were cultured and treated at 37 °C in a humidiﬁed
incubator containing 5% CO2 and maintained free of mycoplasma as de-
termined by Hoechst staining.
2.2. RNA Extraction and RT-PCR
Total RNA for each cell line and clinical sample was isolated using
Tri-Reagent (Molecular Research Center, Inc., Cincinnati, OH) according
to the manufacturer's instructions. Approximately 1 μg of total RNA
from each sample was used to conduct reverse transcription reaction
in 20 μl volume using Superscript II RNase H-Reverse Transcriptase
(Invitrogen Life Technologies, Carlsbad, CA). The synthesized DNA waseither used immediately for PCR ampliﬁcation or was stored at−20 °C
for further analysis.
PCR reaction was performed in a 12.5 μl volume containing 0.5 μl
RT products, 7% DMSO, 1.5 mM dNTPS, 6.7 mM MgCl2, 16.6 mM
(NH4)2SO4, 67 mM tris, 10 mM β-mercaptoethanol, 6.7 μM EDTA,
0.5 μM of both the forward and the reverse primer, and 0.625 units
of Hotstar Taq DNA polymerase (Qiagen, Inc., Chatsworth, CA). Am-
pliﬁcation was carried out with the initial denaturing step at 95 °C
for 15 min, followed by 35 cycles of 95 °C for 30 s, primers speciﬁc
temperature for 30 s, and 72 °C for 1 min in thermal cycler (Hybaid;
PCR Express, Middlesex, UK) with a last extension step of 72 °C for
7 min. The PCR products weremixed with 6× loading buffer contain-
ing 0.5-mg/ml of ethidium bromide and separated by electrophore-
sis on a 2% agarose gel. Oligonucleotide primer set used to amplify
mRNA fragment franking exons 19–23 of DNMT3B with reverse
primer 5′- AAG AGG TGT CGG ATG ACA GG- 3′ locates in exon 23
and forward primer 5′- ATC TCA CGG TTC CTG GAG TG- 3′ locates
in exon 19. An alignment of DNMT3B isoforms surrounding the re-
gion is provided in Supplementary Material I with the primers
highlighted with green color.
2.3. Transgenic Mice Generation
EcoRI and NheI (end blunted) fragment from pcDNA6 V5His-
ΔDNMT3Bdel expression vector was inserted into the SP-C 3.7-
SV40 vector. A Not I and ClaI (end blunted) fragment of IRES-EGFP
from pMIG vector was engineered into EcoRI site of intermediate
SP-C/ΔDNMT3Bdel to generate ΔDNMT3Bdel transgenic constructs.
Transgene construct was veriﬁed by sequencing analysis. For micro-
injection ΔDNMT3B-del transgene was released from cloning vector
by Ndel/DrdI digestion and agarose gel puriﬁed. Transgenic lines
were engineered in C57Bl/6 hybrid strain by the Transgenic/Knockout
Core Facility at the University of Maryland School of Medicine. Trans-
genic integration was conﬁrmed by using a PCR assay of genomic DNA
from tails of individual mice. In NNK challenge experiment, mice were
injected intraperitoneally with NNK (Toronto Research Chemicals, On,
Canada) at 150 mg/kg beginning at 8 weeks of age with one injection
per week for two weeks. 14 month after the ﬁrst injection, mice were
euthanized by CO2, lungs inﬂated with 10% neutral-buffered formalin,
and tissue ﬁxed in the same solution for histology examination.
2.4. Lentivirus Production and Cell Transduction
DNA fragment of DNMT3B-del-IRES-EGFP from transgenic construct
was cloned into MCS of pLVX-Tight-Puro vector of Lenti-X™ Tet-On®
Advanced inducible expression system (Clotech, Mountain View, CA).
Tet-on Virus packaging was performed by transient transfection of
293FT cells with a transfer plasmid and packaging vectors as described
in the manufacturer's user manual. Seventy-two hours after transfec-
tion, the lentiviral particles were collected and ﬁltered, and then con-
centrated using Amicon ultra-15 (Merck Millipore Ltd., Darmstadt,
Germany) by centrifugation at 3000 g for 1 h at 4 °C. Final concentrated
viral particles were aliquot at desired volume into freezer tubes and
stored at−80 °C.
2.5. Flow Cytometry Analysis
HBE4 cells were seeded in a 6-well plate and cultured for 24 h before
virus transduction. The transduction with ΔDNMT3B-del viruses was
carried out with 6 μg hexadimethrine bromide (Polybrene) for 8 h.
The infected cells were then cultured under normal culture medium
with or without 1 μg/ml doxycycline (Dox, a tetracycline derivative)
to induce protein expression for 48 h. Cells were harvested, washed in
PBS, and ﬁxed in 70% ethanol for 24 h at 4 °C. Cells were then washed
twice with PBS, incubated with 500 μl PI/RNase staining buffer (BD
Pharmingen, San Jose, CA, USA) for 45 min, and passed through the
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cyclewas analyzed on a FACSCalibur ﬂow cytometer (Becton-Dickinson,
UK). Ten thousand events were acquired per sample and data were an-
alyzed using CellQuest software (Becton-Dickinson, UK).
2.6. Expression Analysis of Transgenic Mouse Lines by Real-Time PCR
Allprep RNA/DNA/Protein Mini kit (Qiagen, Inc.) was used to pre-
pare total RNA from cell culture. Total RNA was treated with DNase
according to the manufacturer's instructions (Qiagen). One micro-
gram of total RNA were used to converted cDNA by using the Super-
Script II reverse transcriptase kit (Invitrogen, Grand island, NY, USA).
Gene expression of exogenous hΔDNMT3B-del and endogenous
mDNMT3B were determined by TaqMan gene expression assay with a
7900HT Real-Time PCR System detector (Applied Biosystems). Primer
set for hΔDNMT3B-del is: Forward primer: 5′-TGACCGGCCGTTCTTCTG-
3′; Reverse primer: 5′-CCGTGAGATGTCCCTCTTGTC-3′; FAM probe:
5′ 5′-TGTTTGAGAATGTTGTAGCCAT-3′. Other TaqMan gene expres-
sion assays used included mouse Dnmt3B (Mm01240113); nkx2.1
(Mm00447558); Gata6 (Mm00802636); Gapdh (Mm99999915)
(Applied Biosystems, Foster City, CA). The speciﬁc primers and
probe designed by Applied Biosystems were used for ampliﬁcation
of target genes and detection. Mouse GAPDH was used as an internal
control for normalization of gene expression.
2.7. Western Blot Analysis
Proteins from transgenic mice lung tissues or whole cell extractions
were quantiﬁed using the BCA assay (Thermo Scientiﬁc, Rockford,
IL). A total of 50 μg protein extracts were subjected to electrophore-
sis on a NuPAGE 10% Bis-Tris gel (Invitrogen) and transferred to a
polyvinylidene diﬂuoride (PVD) membrane by iBlot gel transfer sys-
tem (Invitrogen, Grand island, NY). Themembranes were blocked for
1 h with 5% non-fat dry milk in TBST (10 mM Tris–HCl, pH 7.4,
100 mM NaCl, 0.1% (V/V) Tween−-20), and successively incubated
with primary antibodies overnight at 4 °C. Anti-EGFP (Sigma, St.
Louis, MO) and anti-DNMT3B (Imgenex, San Diego, CA, USA) anti-
bodies were used to detect DNMT3B expression in transgenic mice
lung tissue, while β-actin was used as an internal control. DNA chro-
mosome aneuploidy related proteins were probed using the follow-
ing antibodies: anti-pH2Ax, anti-53BP and anti-pCHK2 purchased
from Cell Signaling technology (Danvers MA), and Anti-Mad2L2 ob-
tained from Abcam (Cambridge MA). The reaction was followed by
probing with peroxidase-coupled secondary antibodies including
anti-mouse IgG or anti-Rabbit IgG at dilution 1:5000 (Santa Cruz Bio-
technology, Dallas, TX, USA), binding results were visualized using
enhanced chemiluminescence (GE Healthcare).
2.8. Immunohistochemistry
5 μm thick formalin-ﬁxed, parafﬁn embedded tissue sections
from transgenic mice lung were used for immunohistochemistry
staining. Brieﬂy, sections were deparafﬁnized in a series of xylene
baths and then rehydrated using a graded alcohol series. The sections
were then microwaved for 20 min in 10 mmol/L citrate buffer
(pH 6.0) for antigen retrieval. The slides were blocked against en-
dogenous peroxidase activity using 3% hydrogen peroxide solution
for 10 min and then with normal blocking buffer (Vectastain Kit)
for 30 min, sections were incubated overnight at 4 °C with primary
antibodies (anti-53BP1, anti-pH2AX and anti-pCHK2, 1:200 dilu-
tion). After washing with PBS (pH 7.4), the sections were then proc-
essed using standard avidin–biotin immunochemical techniques
(ABC) according to the manufacturer's instruction (Vector Laborato-
ries). Staining was visualized with 3,3-diaminobenzidine tetrahy-
drochloride (Vector Laboratories) as a chromogen. Hematoxylin
was used for counterstaining.2.9. DNA Extraction and MBD-Seq Library Preparation
Three animals per group – wild type and transgenic – were ran-
domly selected. TheWizard Genomic DNA puriﬁcation kit (Promega,
A1120) was employed to extract the genomic DNA from the previous
selected individuals. The concentration of the DNA was determined
by the Qubit dsDNA Broad-Range Assay (Invitrogen, Q32850). The
methyl binding domain protein-enriched genome sequencing
(MBD-Seq) approach was used to identify methylated DNA regions.
MethylCap kit (Diagenode, C02020010) was employed for the acqui-
sition of methylated DNA. Firstly, the extracted DNAwas dissolved to
a concentration of 0.1 μg/μl for a ﬁnal volume of 40 μl in a 1.5 ml tube.
Then, the DNA was fragmented into 300–500 base pairs segments in
a Bioruptor Sonicator. The resultant DNA fragments were ﬁltered in
an agarose gel to visualize and conﬁrm their length. Secondly,
141.8 μl of capture reaction mix containing 12 μl of sheared DNA
and 129.8 μl of buffer B was prepared. From this preparation, 119 μl
was incubated with 1 μl of diluted MethylCap protein on a rotating
wheel at 40 rpm for 2 h and at 4 °C to let the reaction occurs. The re-
maining (22.8 μl) was conserved to use later as input sample. GSH-
coated magnetic beads captured the methylated DNA. The free DNA
was washed off and elutes collected. Three serially increased concen-
trations of elution buffer (150 μl of low, medium and high)were used
for the elution of samples. Puriﬁcation of all fractions and inputs was
achieved by employing the MiniElute PCR Puriﬁcation Kit (QIAGEN,
28006). Lastly, to ascertain the enrichment efﬁciency, qPCR (iCycler
iQ PCR system, Bio-Rad) was performed in duplicates for each sam-
ple. For relative fold enrichment calculation, the applied 2-ΔΔCt
method compared enrichment values of a positive to a negative
primer pair, between experimental (methyl DNA) and reference
(input DNA) samples.
The library for sequencing was assembled following the next steps.
The end repair was achieved using the NEBNext® End Repair Module
(NEB, E6050S). Then, the DNA Polymerase I, Large (Klenow) Fragment
(NEB, M0210L) incorporated a 3′ A into the DNA segments. Additional-
ly, a pair of Solexa adaptors (Illumina) was added to the repaired ends
(T4 ligase, Promega, M1801). The target fragments – 200 to 500 bp in-
cluding adaptors – were selected through ﬁltration in a 2% agarose gel.
PCR, using Phusion® Hot Start High-Fidelity DNA Polymerase (NEB,
M0530S), ampliﬁed puriﬁed DNA templates. Next, DNA quality was
checked. The DNA library was diluted and the concentration veriﬁed
using theQubit assay (Life Technology, Q32850). Finally, the sequencing
was performed in a Solexa 1G GenomeAnalyzer (Illumina) according to
the manufacturer protocol.
2.10. MBD-Seq Data Analysis
Sequence FASTQ ﬁles were checked for quality assurance. After
conﬁrming a satisfactory quality, alignment of theﬁles to themm10 ref-
erence genome, obtained from the UCSC browser (http://genome.ucsc.
edu), was performed employing Bowtie, an ultrafast, memory-efﬁcient
short read aligner software. Initial sequence reads were 50 base pair
long however, the ﬁrst twelve 5′ and three 3′ reads were trimmed to
conserved high sequence quality. Different procedures included in
SAMtools and BEDtoolswere implemented for datamanipulation, ﬁlter-
ing and format transformation. The abundance of reads in a determined
genomic region represents its correspondentmethylation level. Accord-
ingly, the peak-calling step was implemented independently for each
sample using Model Based Analysis of ChIP-Seq (MACS). The program
models empirically the shift of the tags and based on a dynamic Poisson
distribution estimates the local bias, yieldingmore accurate predictions.
The implementation of the DiffBind R package permitted the identiﬁca-
tion of differentially methylated regions (DMRs) between transgenic
andwild typemice (Ross-Innes et al., 2012). The software identiﬁes dis-
tinctly bound sites based on afﬁnity data. The input for DiffBind
consisted of two ﬁles per sample; the output from MACS containing
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DiffBind builds amatrix with the consensus peaks, which have been ob-
tained with a “minimum overlap” of 3, considering the replicates num-
ber for each condition. Next, and after the corresponding contrast is
deﬁned, DiffBinf performs an empirical Bayes method, the edgeR analy-
sis. For this case, the default method trimmedmean ofM-values (TMM)
was used for normalization. This approach subtracts the control reads
and accounts for the effective library size as well. The threshold was
set to 0.1 for the false discovery rate (FDR).
2.11. DMRs Annotation
The ChIPpeakAnno softwarewas employed for the annotation of the
regions with distinct methylation levels (Zhu et al., 2010). The package
reports overlaps, distance and relative position for the inquired entities.Fig. 1. Expression of DNMT3B variants. (A) Illustration of major DNMT3B isoforms (3B1–3B5) w
alternative transcription initiation site and lack of N-terminal 200 amino acids and “del” repres
DNMT3B/ΔDNMT3B-del in lung cancer cell lines by RT-PCR. (D) DNMT3B/ΔDNMT3B-del in bron
pressing bothDNMT3B/ΔDNMT3B andDNMT3B/ΔDNMT3B-del. C2 represents control cells expre
Supplementary Fig. 1. (E) Expression of DNMT3B/ΔDNMT3B-del in surgically resected NSCLC t
DNMT3B/ΔDNMT3B-del or with greater of DNMT3B/ΔDNMT3B. Expression patterns of additionaThe dataset “mmusculus_gene_ensembl” was used for annotation. It
was acquired from biomart and corresponds to the genome GRCm38
(mm10), the same one used for the alignment. Information regarding
CpG islands was retrieved from UCSC and later used as feature input
in the ChIPpeakAnno package.
3. Results
3.1. Predominant Expression of DNMT3B/ΔDNMT3B-del in NSCLC Cell Lines
DNMT3Bmay have various expression forms and Fig. 1A illustrates
the possible transcription variants of DNMT3B4 as an example. We
used primers ﬂanking exons 19 to 23 of DNMT3B and ΔDNMT3B to de-
termine the expression patterns of the DNMT3B and ΔDNMT3B region
corresponding to the enzymatic domain in 4 immortalized normalith the excluded exon(s) with brown numbers. (B) “Δ” is for DNMT3B subfamily with an
ents isoforms excluding exons 21, 22 or both 21 and 22 (shaded boxes). (C) Expression of
chial brushing samples from smokers without lung cancer. C1 represents control cells ex-
ssing onlyDNMT3B/ΔDNMT3B-del. Expression patterns of additional samples are shown in
issues. *, represent tumors with either equal expression levels of DNMT3B/ΔDNMT3B and
l bronchial brushing and primary NSCLC tissues are shown in Supplementary Fig. 1.
Fig. 2.Generation of transgenic mouse lines overexpressingΔDNMT3B4-del in lungs. (A) Structure of theΔDNMT3B4-del transgenic construct. Major components of the transgene and the
primer sets used for genotyping. (B) Results of real time RT-PCRdetermining expression of the exogenous humanΔDNMT3B4-del and the endogenousmouseDnmt3B in lungs of the trans-
genic mouse lines. Relative expression levels were normalized with endogenous control GAPDH.
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surprise, 9 (75%) of the 12 NSCLC cell lines expressed only or pre-
dominantly DNMT3B and ΔDNMT3B forms lacking exons 21, 22 or
both 21 and 22 whereas the HBE cells expressed equal quantity of
DNMT3B and ΔDNMT3B transcripts with and without the exons 21–
22 (Fig. 1B). All of the RT-PCR products were veriﬁed by direct se-
quencing of the excised bands. The sequences obtained are consis-
tent with the predicted DNMT3B and ΔDNMT3B splicing variants.
We termed the transcripts lacking exons 21, 22 or both 21 and 22
as DNMT3B/ΔDNMT3B-del.
The transcripts lacking one or two of exons 21 and 22 would en-
code truncated proteins lacking motifs VII and VIII, the TRD (target
recognition domain), or a part of motif IX (Robertson et al., 1999),
thus eliminating the DNA methyltransferase activity. The results,
therefore, indicate that the majority of NSCLC cell lines have either
no or low levels of DNMT3B enzymatic activity and suggest that the
enzymatic activity ofΔDNMT3B or DNMT3B is not required for creat-
ing the altered DNAmethylation landscapes in these NSCLC cells. Be-
cause ΔDNMT3B is the major transcripts of DNMT3B in NSCLC (Wang
et al., 2006b), it was previously assumed that ΔDNMT3B-del is in-
volved in the formation of aberrant DNA methylation patterns ob-
served during lung tumorigenesis.
To rule out the possibility that the observed DNMT3B/ΔDNMT3B-
del expression patterns were a cell culture artifact, we analyzed
bronchial epithelial cells obtained from 30 healthy heavy smokers
during bronchoscopy procedure. Twenty-eight (93%) of the 30Fig. 3.Microscopic changes in lungs in the transgenic mice overexpressing ΔDNMT3B4-del. (A)
renchymal inﬂammatory cell aggregates and tumor-like structure.WT:wild-typemouse; TG: tra
the transgenic animals. (C) pH 3 staining in lungs of wild-type mouse (WT) and transgenic mosamples had adequate quality of RNA allowing accurate RT-PCR anal-
ysis and data interpretation. All the 28 samples exhibited expression
patterns consistent with either equal quantity of DNMT3B/ΔDNMT3B
and DNMT3B/ΔDNMT3B-del or a greater quantity of DNMT3B/
ΔDNMT3B (Fig. 1C and Supplementary Fig. 1A), which is the similar
pattern as observed in the HBE cells. We then analyzed 119 primary
NSCLC tumors from patients with surgically resected NSCLC for
DNMT3B/ΔDNMT3B expression patterns using the same primer set
used for cell lines and the primary bronchial epithelial cells. We ob-
served that 111 (93%) of the 119 tumors expressed predominantly
DNMT3B/ΔDNMT3B-del including 47 (39%) tumors with no detect-
able DNMT3B/ΔDNMT3B (Fig. 1D and Supplementary Fig. 1B),
which is consistent with the results observed in the NSCLC cell
lines. Together, these results indicate that the loss of DNMT3B/
ΔDNMT3B expression or overexpression of the enzymatic domain
lacking DNMT3B/ΔDNMT3B-del is a common abnormality not only
in cultured NSCLC cells but also in primary NSCLC tumors.
To determine if DNMT3B/ΔDNMT3B-del transcripts can be trans-
lated into proteins, we attempted to measure the corresponding pro-
tein products using Western blot analysis. Unfortunately, all the
commercially available antibodies against DNMT3B we tested as
well as antibodies generated in our own laboratory, while effective
in detecting DNMT3B expressed and puriﬁed in bacteria, were
found to be non-speciﬁc to DNMT3B when used for total cellular pro-
tein extracts. We therefore tested plasmids containing either
ΔDNMT3B or ΔDNMT3B-del isoforms by transfecting H1299 cellsThree major morphological changes were observed: bronchial epithelial hyperplasia, pa-
nsgenicmouse. (B)Accumulative incidence ofmicroscopic alterations observed in lungs of
use (TG).
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sponding recombinant proteins using an anti-tag antibody. We de-
tected both ΔDNMT3B and the shortened ΔDNMT3B-del isoforms
byWestern blot analysis using an anti-V5-tag antibody (Supplemen-
tary Fig. 2A), indicating that the transcripts of these DNMT3B iso-
forms can be translated into proteins in cells. We further
transfected HEK293 cells with ΔDNMT3B4-del-GFP fusion protein
construct and found ΔDNMT3B4-del was predominantly located in
nucleus (Supplementary Fig. 2B).
3.2. Transgenic Mice with Lung-Speciﬁc Expression of ΔDNMT3B4-del
To determine the causal relationship between ΔDNMT3B-del and
the landscape changes in global DNA methylation patterns in lung tu-
morigenesis, we constructed ΔDNMT3B4-del transgenes (Δ3B4DG)
under the control of surfactant protein-C promoter (SPC) aiming to
overexpressΔDNMT3B4-del speciﬁcally inmouse lung epithelial and al-
veolar cells which express endogenous SPC (Fig. 2A). The reason of
selecting ΔDNMT3B4-del was based on our earlier observation that
ΔDNMT3B4 is the DNMT3B isoform expressed at the highest level
among the NSCLC cell lines and primary NSCLC tissues examined
(Wang et al., 2007). Microinjection of the transgene into pro-nuclei of
fertilized eggs gave rise to total 30 live pups, 6 of them carried SPC/
Δ3B4DG transgene with 4 of them achieved germ-line transmission.
These founder lines were named as: Tg(SPC-DNMTΔ3B/DG)1lm,
Tg(SPC-DNMTΔ3B/DG)3lm, Tg(SPC-DNMTΔ3B/DG)25lm and Tg(SPC-
DNMTΔ3B/DG)27lm according to MGI-Guidelines for Nomenclature of
Gene, Genetic Markers, Alleles, and Mutations in Mouse and Rat:
http://www.informatics.jax.org/mgihome/nomen/gene.shtml.
To verify expression of the transgene, we analyzed F1 litters of these
transgenic founder lines using real-time RT-PCR. The ΔDNMT3B4-del
transgene was found expressed at variable levels in the mouse lung tis-
sues of Tg(SPC-DNMTΔ3B/DG)1lm, Tg(SPC-DNMTΔ3B/DG)3lm and
Tg(SPC-DNMTΔ3B/DG)27lm litters but not in Tg(SPC-DNMTΔ3B/
DG)25lm mice (Fig. 2B). Tg(SPC-DNMTΔ3B/DG)25lm mice were ex-
cluded for further analysis. The lack of the transgene expression in
Tg(SPC-DNMTΔ3B/DG)25lm mice was likely due to a positional effect
of the transgene insertion. For more accurate interpretation of the
data, we measured the endogenous levels of mouse Dnmt3b expression
in the lungs using real-time RT-PCR. As expected, endogenous Dnmt3b
expression levels were comparable among different transgenic mouse
lines but lower compared to the expression levels of the transgene,
ranging from less than 10% for Tg(SPC-DNMTΔ3B/DG)3lm mice to
about 50% for Tg(SPC-DNMTΔ3B/DG)27lmmice (Fig. 2B). Thus,we gen-
erated transgenic mice overexpressing ΔDNMT3B4-del in the mouse
lung tissues.
3.3. Phenotypes in ΔDNMT3B-del Overexpressing Mice
Grossly, we found no apparent developmental defects in the
transgenic animals. The animals lived normally and were able to
breed. To determine the impact of ΔDNMT3B4-del in lungs of the an-
imals, we examined the lungs from 43 Tg(SPC-DNMTΔ3B/DG) mice
with age ranging from 12 to 16 months and 20 age matched wild-
type mice. No gross abnormalities in the lungs were observed com-
paring the transgenic mice with wild-type mice during necropsy.
We then examined the lung tissues of eachmouse in a series of sections
of parafﬁn-embedded formalin-ﬁxed lung tissues. Under microscope
magniﬁcation, we observed several morphological changes including
enlarged lung alveoli in the distal bronchi, increased bronchial epitheli-
umhyperplasia (Fig. 3A up right panel), enhanced parenchymal inﬂam-
matory aggregates (Fig. 3A low left panel) and tumor-like structures
(Fig. 3A low right panel) compared to the lungs from wild-type mice
(Fig. 3A up left panel).
Among the 43 Tg(SPC-DNMTΔ3B/DG) mice, 17 were from Tg(SPC-
DNMTΔ3B/DG)1lm, 13 from Tg(SPC-DNMTΔ3B/DG)3lm and 13 fromTg(SPC-DNMTΔ3B/DG)27lm. We observed bronchial epithelial hyper-
plasia in the lungs from 25 (58%) of the 43 mice compared to 1 (5%)
of the 20 wild-type mice. The difference of presenting bronchial epithe-
lial hyperplasia is statistically signiﬁcant between the ΔDNMT3B-del
overexpressing transgenic animals and the wild-type animals (P b
0.0001 by Fisher's Exact Test, Fig. 3B). The hyperplastic lesions in the
transgenic lungs showed increased number of epithelial cells positive
for phosphorylated Histone H3 protein (pH 3), indicating augmented
proliferation potentials of the epithelial cells in lungs of the transgenic
animals (Fig. 3C). Ten (23%) of the transgenic animals presented with
parenchymal inﬂammatory aggregates and 5 (12%) developed tumor-
like structures in the lungs compared to 3 (15%) and none (0%) for the
20wild-typemice, respectively (Fig. 3B), but the differences are not sta-
tistically signiﬁcant.3.4. Changes of DNAMethylation Landscape in Lungs of the TransgenicMice
We ﬁrst examined expression levels of two major transcriptional
factors, Nkx2.1 and Gata6 which regulate the expression of SPC gene
and are critical in lung development, in lungs of the transgenic mice.
As expected, lungs were the only tissue that expressed both Nkx2.1
andGata6 at a high level in both transgenic andwild-typemice (Supple-
mentary Fig. 3), suggesting thatΔDNMT3B4-del transgene expression in
the lungs did not impact SPC promoter activity in lungs of the transgenic
mice. Hence, ΔDNMT3B4-del transgene expression itself was also un-
likely affected by the resulting morphological changes in the lungs.
To determine potential impact in global DNA methylation patterns
in the lungs of the transgenic mice elicited by ΔDNMT3B4-del overex-
pression, we ﬁrst analyzed the overall levels of DNA methylation in
the genome of the mouse lungs using Imprint®Methylated DNA Quan-
tiﬁcation kit (Sigma). Comparedwith DNA samples obtained from lungs
of wild type animals, DNA samples obtained from lungs of ΔDNMT3B4-
del expressing mice exhibited a signiﬁcantly reduced amount of DNA
methylation (P b 0.05) but not DNA samples obtained fromheart tissues
where no transgene expression was detected (Supplementary Fig. 4),
indicating that DNA samples from lungs of the transgenic mice were
globally hypomethylated. Such DNA hypomethylation may be used to
explain the observed phenotypes in lung tissues of the transgenic
mice as this type of abnormalities has been reported in the early tumor-
igenesis (Jones and Baylin, 2007).
We then wanted to determine the impact of the transgene ex-
pression on global DNAmethylation patterns in a more speciﬁc man-
ner. To do this, we used methyl binding domain protein-enriched
genome sequencing (MBD-Seq) approach (Decock et al., 2012; Lan
et al., 2011; Li et al., 2010) to analyze methylated DNA regions in
the genomic DNA samples with base pair resolution. For our analysis,
we constructed 6 libraries of genomic DNA samples frommouse lung
tissues obtained from both wild-type and transgenic mice (for each
group, n = 3 biological replicates).
More than 76 million reads were obtained ranging from 8.6 million
to N17 million reads for each library. The raw data has been deposited
in NCBI database and can be access through: http://www.ncbi.nlm.nih.
gov/geo/query/acc.cgi?acc=GSE68922. Among the reads, 91.5 to
96.5% of the reads for eachMBD-Seq sampleweremapped tomouse ge-
nome (Supplementary Table 1). We used ChIPpeakAnno software for
annotating the regions with distinct methylation levels (Zhu et al.,
2010). Ignoring the total number of reads, the samples derived from
transgenic and wild-type mice demonstrated similar alignment levels
(Supplementary Table 1), an indication of the robustness of themethod.
We identiﬁed 92,205 methylated regions that overlap in at least three
samples and these regions were used for further analyses. The overall
read counts aligned to a normalized gene body are shown in Fig. 4A.
Each genemapped with reads was converted its gene length from tran-
scription start site (TSS) to transcription end site (TES) as 100% of the
gene body in order to make the measurements comparable.
1347M.Z. Ma et al. / EBioMedicine 2 (2015) 1340–1350We observed that the DNAmethylation level was consistently lower
in the gene bodies of DNA samples from lungs of the wild-type mice
compared with DNA samples from the transgenic mice (Fig. 4A). How-
ever, this pattern reversed at theCpG island shores (Fig. 4B),whereDNAFig. 4. DNA methylation patterns in lungs of wild-type and transgenic animals measured by M
(green) and transgenic (brown) animals. The geneswere transformed to a bodypercentage from
gene bodies with extended intergenic regions and CpG island shores for samples from wild-ty
samples from wild-type and transgenic animals. (D) Clustering of genomic DNA samples from
each sample group (wild-type and transgenic). Signs + and− illustrate the regions with incre
test). (F) Summary of the locations of DMRs regarding features, genes and CpG islands. (G) Dis
ative to transcription starting site (TSS).samples from the wild-type mice exhibited a signiﬁcantly higher cyto-
sine methylation than DNA samples from the transgenic mice. The
scale for the y-axis is much smaller than the observed in chart corre-
spondent for gene body but the shades from the standard error do notBD-Seq. (A) Reads of DMR aligned to normalized gene bodies for samples from wild-type
its length tomake themeasurements comparable. (B) Overall reads aligned to normalized
pe and transgenic animals. (C) Highlight of overall reads aligned to intergenic regions for
transgenic and wild-type animals based on DMRs. (E) Depiction of DMR methylation for
mented afﬁnity in wild-type and transgenic group, respectively. * (p b 0.001 byWilcoxon
tribution of DMRs of both hyper-methylated and hypo-methylated in transgenic mice rel-
1348 M.Z. Ma et al. / EBioMedicine 2 (2015) 1340–1350overlap, except in the peaks observed inside the−1000 bp of the left of
the CpG islands. Interestingly, the intergenic regions also showed a clear
opposite pattern compared to the gene body (Fig. 4C). Although the dif-
ferences between the two sample groups are small in values for the nor-
malized counts, the differences are statistically highly signiﬁcant (P b
0.0001).
The DiffBind R packagewas applied for the identiﬁcation of differ-
entially methylated regions (DMRs) between the transgenic and
wild type mice (Ross-Innes et al., 2012). A total of 407 genomic re-
gions were identiﬁed to have distinct methylation levels (Supple-
mentary Table 2). When these DMRs were used to classify the
animals, they perfectly clustered the transgenic and wild-type samples
together (Fig. 4D), which validated the reliability of DMR detection
method. Among the 407 DMRs, 103 (25%) were hypomethylated and
304 (75%) were hypermethylated in samples from the transgenic
mice. As depicted in Fig. 4E, DNA methylation patterns from the trans-
genic mice showed a higher methylation but also a broader variability
compared to those from wild-type mice. The locations of the DMRs in
genomic DNA regions as well as in CpG islands are summarized in
Fig. 4F. Approximately 40% of the DMRs are located inside genes where-
as most of the remaining DMRs are equally distributed in the down-
stream or upstream of genes. Interestingly, only 6% of the DMRs
contain a CpG island. The rest remains in similar proportion upstream
or downstream of the CpG islands. The hypermethylated DMRs in tis-
sues from the transgenic mice tend closer to transcriptional starting
sites of genes whereas the hypomethylated DMRs more widespread
and located downstream of transcription start sites (Fig. 4G).
3.5. Hyperplasia and Genome Instability in Lungs of the Transgenic Mice
It has been suggested that cells with altered DNA methylation are
susceptible to undergoing chromosomal loss, gain, or rearrangement
(Dodge et al., 2005; Tuck-Muller et al., 2000).We examined the expres-
sion of DNA damage response genes including 53BP1, pCHK2 and
pH2AX in lung tissue sections. Comparing to lungs of wild-type mice,Fig. 5. Expression of genes associated with DNA damage induced by overexpression of ΔDNM
lungs of wild-type and transgenic animals. (B) Scheme of major components in inducible exp
tet-op promoter through IRES fragment in the presence of 1 μg/ml Dox, an indirect proof of ΔD
bronchial epithelial (HBE4) cells infectedwith lentivirus hosting the inducible expression vecto
ploidy and DNA damage associated proteins in HBE4 cells infected with lentiviral particles befthe hyperplastic lung tissues from the transgenicmice appear to express
higher levels of 53BP1 and pH2AX (Fig. 5A).
To substantiate the ﬁndings observed in the transgenic mice, we
overexpressed ΔDNMT3B4-del in immortalized normal bronchial ep-
ithelial (HBE4) cells by infecting the cells with lentivirus containing
ΔDNMT3B4-del expressing cassette as depicted in Fig. 5B. The
ΔDNMT3B4-del expression in the cells could be induced by treating
the cells with tetracycline for 48 h as shown in Fig. 5C. Expression
of ΔDNMT3B4-del signiﬁcantly increased the percentage of cells in
G2/M phase (Fig. 5D). The percentage of the cells with abnormal
DNA content (NG2 cells) were also increased, indicating that the
overexpression of ΔDNMT3B4-del might have caused DNA damage
and formation of aneuploidy, which are frequently found in the
early stage of tumorigenesis (Kops et al., 2005; Sugai et al., 2003). Ex-
pression of DNA damage response genes 53BP1, pCHK2 and pH2AX
were evaluated in the inducible ΔDNMT3B4-del expression cells.
Consistent with the ﬁndings observed in lungs of the transgenic
mice, pH2AX and 53BP1 proteins were signiﬁcantly elevated with
no notable change in the expression of pCHK2 (Fig. 5E). Protein
Mad2L2 that is associated with cell aneuploidy was also increased
after induction of ΔDNMT3B4-del expression (Fig. 5E).
3.6. Promoting Tumor Formation in Lungs of Carcinogen Treated Transgenic
Mice
Genomic instability caused by aberrant expression ofΔDNMT3B4-del
could prime cells for acquisition of genetic mutations, resulting in an in-
creased rate of tumor formation. To test this possibility, we treated the
transgenic mice with tobacco carcinogen 4-(Methylnitrosamino)-1-
(3-pyridyl)-1-butanone (NNK) to determine whether overexpression
ofΔDNMT3B4-del can confer an increased rate of lung cancer formation.
C57Bl/6 mouse strain, from which ΔDNMT3B-del transgenic lines were
made, is generally resistant to NNK challenge (Ryan et al., 1987). Both
transgenic mice and their wild-type littermates were treated with
NNK (150 mg/kg) beginning at 8 weeks of age with one injection perT3B4-del. (A) Immunohistochemistry for proteins as indicated in a series of sections from
ression of ΔDNMT3B4-del in lentiviral expression system. (C) EGFP expression driven by
NMT3B4-del expression. (D) Cell cycle distributions measured in the immortalized normal
rs of ΔDNMT3B4-del before and after 48 h treatment with 1 μg/ml Dox. (E) Levels of aneu-
ore and after 48 h treatment with Dox.
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surface lung tumor was observed by gross examination in both groups
of mice. Nevertheless, 5 out of 6 transgenic mice treated with NNK
showed microscopic lung adenocarcinoma or tumor-like structures
(Fig. 6) whereas no notable morphological change was observed in
the lungs of 5 wild-type mice (P= 0.015 by Fisher's Exact Test).
4. Discussion
Genomic DNA methylation is established and maintained by two
distinct processes: de novo DNA methylation which is mediated by
DNMT3A, DNMT3B and DNMT3L (isoform lacking the characteristic
C-terminal catalytic domain) and DNA methylation maintenance
which is catalyzed by DNMT1. Overexpression of DNMT3B has been
reported in many cancer types including NSCLC. Furthermore, differ-
ent DNMT3B transcripts derived from alternative splicing or alterna-
tive use of transcription initiation site have been reported (Ostler
et al., 2007; L. Wang et al., 2006), which may impact the pattern of
DNA methylation and gene expression (Wang et al., 2007). In this
study, we focused on DNMT3B variants with alternative splicing at
the 3-prime region without exons 21, 22 or both 21 and 22. Such ex-
clusions result in a disruption of the catalytic units of the methyl-
transferase and therefore DNA methyltransferase activity. Our
analysis showed that almost half of NSCLC cell lines and primary
NSCLC tumors examined expressed only the DNMT3B variants lack-
ing exons 21, 22 or both 21 and 22 (termed ΔDNMT3B-del), whereas
the normal bronchial epithelial cells expressed DNMT3B variants
with and without the exons in a ratio of approximately 1:1. This ﬁnd-
ing is somewhat surprising because of the common belief that in-
creased DNA methyltransferase activity contributes to abnormal
DNA methylation patterns in cancers. While exact mechanisms re-
main to be determined, our ﬁnding suggests that a proper ratio of
DNMT3B/ΔDNMT3B and DNMT3B/ΔDNMT3B-del is important for
maintaining DNA methylation landscapes, wherein reduced levels of
DNMT3B/ΔDNMT3B and overexpression of catalytically deactivated
DNMT3B/ΔDNMT3B-del contribute to altered DNA methylation pat-
terns in lung tumorigenesis.
To substantiate our hypothesis, we generated transgenic mice over-
expressing ΔDNMT3B4-del speciﬁcally in lung epithelial and alveoli
cells. As expected, induced overexpression of ΔDNMT3B4-del caused
an increased lungductal epithelial hyperplasia and inﬂammatory aggre-
gates in most of the transgenic mice. However, none of the lesions
progressed to tumors even animals aged up to year and a half, suggest-
ing this factor alone is a modiﬁer and not sufﬁcient to transform lung
epithelial cells to malignancy. It is possible that overexpressed
ΔDNMT3B4-del,which lacks the catalytic domain of DNA methyltrans-
ferase, competes with de novo DNA methyltransferase 3A and 3B to
counteract the activity of the de novo DNA methylases. This dominant
negative effect could lead to altered DNA methylation patterns in theFig. 6.Microscopic tumors in lungs of the transgenic animals treatedwith tobacco carcinogen N
animals with tumor-like lesions (TG-tumor-like) and adenocarcinomas (TG-tumor).cancer cell genome, an effect similarly caused by DNMT3L observed in
embryonic stem cells (Neri et al., 2013). Consistent with this argument,
overall CpG sites methylated in genomic DNA from lungs of transgenic
mice were signiﬁcantly lower as determined by the ELISA-based assay.
Interestingly, genomic DNA from lungs of the transgenic mice exhibited
an increased methylation in the gene bodies but hypomethylation in
intergenic regions, similar to genomic DNA methylation patterns
found in lung cancer cells. Bearing inmind that changes of DNAmethyl-
ation pattern were observed in genomic DNA from lungs of the
transgenic animals rather than tumor cells, our results suggest that
overexpression of ΔDNMT3B4-del is able to disturb the normal DNA
methylation pattern to facilitate early stage molecular alterations and
morphologic changes consistent with initiation of tumorigenesis.
The global DNA methylation patterns observed in lung tissues from
the transgenic mice overexpressing ΔDNMT3B4-del showed some simi-
larity to those observed in human cancers, particularly the global DNA
hypomethylation and regional hypermethylation in certain CpG islands.
It has been reported that DNA hypermethylation of CpG islands causes
inactivation of tumor suppressor genes through gene promoter sup-
pression (Baylin and Herman, 2000). In addition, global genomic hypo-
methylation has been reported to be associatedwith genomic instability
(Putiri and Robertson, 2011). Of the proteins associatedwith DNA dam-
age response we examined, 53BP1 and pH2AX were signiﬁcantly in-
creased in lungs of the transgenic animals as well as in normal lung
epithelial cells overexpressing ΔDNMT3B4-del. Consistent with this ob-
servation, immortalized normal bronchial epithelial cells with induced
ΔDNMT3B-del expression displayed increased cell populations accumu-
lated in G2 phase (48 h post-induction) as well as increased activation
of MDM2L, a gene associated with aneuploidy. These results support
the role of ΔDNMT3B4-del in reducing genomic instability.
In a previous study, we have shown that ΔDNMT3B4 may preferen-
tially target certain CpG enriched promoters (Wang et al., 2007) but no
consensus targeting sequence was identiﬁed. In this study, while over-
expressing ΔDNMT3B4-del resulted in an altered DNAmethylation pat-
tern in lungs of the transgenic mice, we did not seek to identify
consensus sequences preferentially targeted by the DNMT3B isoform
due to the complexity in formation of DNA methylation landscape and
the heterogeneity nature of the lung tissues where various cell types
were pooled together for the analysis. Such attempts will be necessary
in future studies by analyzing data obtained frommicro-dissected bron-
chial epithelial cells and tumor cells of the mice.
It is important to note that expression of ΔDNMT3B4-del alone was
insufﬁcient to transform lung epithelial cells in our animal model. This
is not surprising because aberrant DNA methylation changes are early
events in tumorigenesis andmultiple factors are necessary for develop-
ment of clinically relevant cancer. In fact, the transgenic mice became
susceptible for lung cancer development and developed lung cancer
when challenged with NNK treatment. While ΔDNMT3B4 is the most
abundant isoform expressed in NSCLC (J. Wang et al., 2006; L. WangNK. Typical morphology of lung sections fromwild-type (WT) animals and transgenic (TG)
1350 M.Z. Ma et al. / EBioMedicine 2 (2015) 1340–1350et al., 2006), abnormal expression of other isoforms are also observed in
NSCLC. It will be important to determine the potential impact of other
isoforms in DNA methylation patterns and lung tumorigenesis both
alone and in combination with ΔDNMT3B4.
Taken together, our study demonstrates an important role of
DNMT3B/ΔDNMT3B-del in lung tumorigenesis and developed a
transgenic mouse model valuable for future in vivo studies to better
understand mechanisms regarding how the DNA methylation
changes during lung tumorigenesis as well as develop strategies to
prevent lung cancer by targeting DNMT3B/ΔDNMT3B-del induced
tumorgenesis. Because current demethylation agents used or tested
in clinic are non-speciﬁc to isoforms of DNA methyltransferases,
our ﬁndings raise the possibility of selectively targeting individual
isoforms, at least DNMT3Bs, to improve efﬁciency and reduce poten-
tial side effects. Further studies focusing on comparative analysis of
individual isoforms will improve our understanding of the biological
impacts of these isoforms and facilitate the translation of the knowl-
edge into development of clinical applications.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.ebiom.2015.09.002.
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